Navigation Links
NSAIDs benefit overweight breast cancer patients, study finds
Date:8/14/2014

AUSTIN, Texas Researchers have determined that postmenopausal overweight or obese breast cancer patients receiving hormone therapy as part of their treatment and who use nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen have significantly lower breast cancer recurrence rates and a sizable delay in time to cancer recurrence.

The findings, published in the Aug. 14 edition of Cancer Research, suggest a new possibility for reducing the incidence of breast cancer recurrence among overweight and obese postmenopausal women, who have a comparatively higher risk of recurrence.

Using a retrospective analysis of human subjects and cell cultures, the researchers determined that NSAID use reduces the recurrence rate of the most common form of breast cancer, ERα positive breast cancer, by 50 percent and extends patients' disease-free period by more than two years. ER positive breast cancers, which grow in response to exposure to the hormone estrogen, account for about 75 percent of diagnoses.

Cancer researcher Linda deGraffenried of The University of Texas at Austin designed the study, working closely with Andrew Brenner, an oncologist from the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, and Murali Beeram, a cancer specialist from the START Center for Cancer Care in San Antonio, Texas.

The investigators caution that these results are preliminary, and studies are being conducted to confirm these initial findings.

"Overweight or obese women diagnosed with breast cancer are facing a worse prognosis than normal-weight women," says deGraffenried. "We believe that obese women are facing a different disease. There are changes at the molecular level. We seek to modulate the disease promoting effects of obesity."

The investigators first examined medical records of 440 breast cancer patients, comparing the prognoses of those who took NSAIDs with those who did not.

The researchers designed a second study to examine how breast cancer cells behave in the body. By bathing ERα positive breast cancer cells in blood serum from obese women, they hoped to mimic the environment that encourages tumors to grow, proliferate and metastasize.

Although the mechanism causing breast cancer in obese women to be more aggressive and less responsive to treatment is not completely understood, the researchers believe that inflammation plays a pivotal role. Their findings also suggest inflammation negatively affects the effectiveness of aromatase inhibitors, a class of cancer drugs commonly prescribed to prevent cancer recurrence.

"Clinicians are finding that the five-year recurrence rate for postmenopausal women is much higher on aromatase inhibitors when the patient is obese," says deGraffenried. "We would like to identify which women are most likely to benefit from interventions like adding NSAIDs to treatment regimens."

Laura Bowers, who led the cell culture segment of the study, suggests that overweight or obese postmenopausal women those at greater risk for breast cancer development might benefit from taking a low-dose aspirin daily. "What this study does is present great promise that a fairly inexpensive and nontoxic agent might benefit obese and overweight breast cancer patients who are at a higher risk of aromatase inhibitor failure but further studies are needed to confirm these results," says Bowers.

The research team is planning a larger prospective study to identify disease biomarkers and monitor patient response to the addition of NSAIDs to breast cancer treatment.


'/>"/>

Contact: Kimberly Atkins
kimberly.atkins@austin.utexas.edu
512-471-3151
University of Texas at Austin
Source:Eurekalert

Related biology news :

1. Patients use OTC NSAIDs even when they have a high risk of serious side effects
2. Artificial wetlands can provide benefits over the long haul
3. Strong scientific evidence that eating berries benefits the brain
4. Consumers need simple, concise messages about benefits of phytonutrients
5. Sexual reproduction brings long-term benefits, study shows
6. Why letting salmon escape could benefit bears and fishers
7. Treatment to benefit African infants at risk of endemic fever
8. New research underscores the health benefits of fibers, including bone health
9. How will the US biotechnology industry benefit from new patent laws?
10. NHS set to benefit from UK-led technologies
11. Targeting tuberculosis hotspots could have widespread benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology: